At the news
? NEUTRALIMPACT 2/10 6-K filed Aug 19, 2026 at 09:43 ET
AstraZeneca filed a Form 6-K reporting the vesting of a long-term performance share award to CFO Aradhana Sarin. The award, granted in 2021 under the AstraZeneca Performance Share Plan, vested on 17 August 2026 after a three-year performance period and a two-year holding period. This is a routine administrative disclosure regarding executive compensation and has no material impact on the company's financials or operations.
- CFO Aradhana Sarin received 11,133 ordinary shares upon vesting of a 2021 performance share award.
- The shares were acquired for nil consideration under the AstraZeneca Performance Share Plan.
- The fair market value at vest was £114.60 per share.
- Shares were withheld to satisfy tax obligations; the net change in beneficial interest is not disclosed.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access